Immune Checkpoint Therapy-Current Perspectives and Future Directions

Authors

Padmanee Sharma
Sangeeta Goswami
Deblina Raychaudhuri
Bilal A Siddiqui
Pratishtha Singh
Ashwat Nagarajan
Jielin Liu
Sumit K Subudhi
Candice Poon
Kristal L Gant
Shelley M Herbrich
Swetha Anandhan
Shajedul Islam
Moran Amit
Gayathri Anandappa
James P Allison

Publication Date

4-13-2023

Journal

Cell

DOI

10.1016/j.cell.2023.03.006

PMID

37059068

Abstract

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT.

Keywords

Humans, B7-H1 Antigen, Immunotherapy, Neoplasms, Clinical Trials as Topic, Immune Checkpoint Inhibitors, CTLA-4, ICT, PD-1, PD-L1, combinatorial biomarkers, cytotoxic T lymphocyte-associated protein 4, immune checkpoint therapy, immune-related adverse events, irAEs, programmed cell death protein 1, programmed death ligand 1, reverse translation

Published Open-Access

yes

Recommended Citation

Sharma, Padmanee; Goswami, Sangeeta; Raychaudhuri, Deblina; et al., "Immune Checkpoint Therapy-Current Perspectives and Future Directions" (2023). Faculty, Staff and Student Publications. 4204.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4204